Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc. (KYMR): 8 pipeline candidates · 1 upcoming catalyst · ~21 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
21.4 months
D/E 0.08 · 19% dilution
Lead: Phase 2
8 candidates
1 upcoming, next in ~377d
0 buys · 79 sells (180d)
A transparent, data-derived signal for Kymera Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$7.4B
Cash
$144.1M
Quarterly Burn
$88.8M
Runway
21.4 mo
Revenue
$34.4M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (8 candidates)
| Drug | Phase |
|---|---|
| KT-253 | Phase 1 |
| KT-294 | Preclinical |
| KT-295 | Preclinical |
| KT-333 | Phase 1 |
| KT-474/SAR444656 | Phase 2 |
| kt-485/sar447971 | Preclinical |
| KT-579 | Phase 1 |
| KT-621 | Phase 2 |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
254
Total value held
$6.05B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 11,699,950 | $974.5M |
| baker bros. advisors lp | 8,657,242 | $721.1M |
| vanguard capital management llc | 5,760,648 | $479.8M |
| bvf inc/il | 5,502,710 | $458.3M |
| blackrock, inc. | 5,060,876 | $421.5M |
| wellington management group llp | 3,889,687 | $324.0M |
| vanguard portfolio management llc | 2,874,056 | $239.4M |
| state street corp | 2,389,767 | $199.0M |
| capital research global investors | 1,673,275 | $139.4M |
| geode capital management, llc | 1,645,350 | $137.1M |
Showing top 10 of 254 institutional holders of Kymera Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Kymera Therapeutics, Inc.'s pipeline?
Kymera Therapeutics, Inc. (KYMR) has 8 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Kymera Therapeutics, Inc.'s lead drug candidate?
Kymera Therapeutics, Inc.'s most advanced tracked candidate is KT-253 (Phase 1) for Treatment of relapsed or refractory high grade myeloid malignancies, acute lymphocytic leukemia (ALL), lymphomas, and solid tumors; orphan designation for acute myeloid leukemia.
What is Kymera Therapeutics, Inc.'s next catalyst?
Kymera Therapeutics, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: kt-621" — expected June 30, 2027.
What is Kymera Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Kymera Therapeutics, Inc. has approximately 21.4 months of cash runway.
What is Kymera Therapeutics, Inc.'s market capitalization?
Kymera Therapeutics, Inc.'s market capitalization is approximately $7.4B.
Get the full picture on Kymera Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.